Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) slid 30% on Thursday after the company released interim Phase 1 results from its INLIGHT trial testing WVE-007 as a treatment for obesity.
The six-month readout from the 240 mg cohort showed a placebo-adjusted 14% reduction in visceral fat among otherwise healthy participants with overweight or obesity. That cohort comprised 32 individuals with an average body mass index (BMI) of 32 kg/m2, a figure the company notes is markedly lower than the roughly 37 kg/m2 average commonly enrolled in later-stage obesity trials.
Wave highlighted additional body-composition findings: a 16.5% improvement in visceral fat-to-muscle ratio from baseline following the single 240 mg dose. The company compared that change to a 12.2% improvement observed with weekly semaglutide dosing in a separate Phase 2 trial whose participants had higher BMI. At six months, WVE-007 also produced a placebo-adjusted 3.3% reduction in waist circumference and a 0.9% reduction in body weight, while lean mass increased by 2.4%.
On safety, the company reported that WVE-007 remained generally safe and well tolerated up to 600 mg, with no treatment discontinuations or severe adverse events recorded. Wave also said Serum Activin E reductions were durable through at least seven months, with mean maximum reductions of up to 88%, a finding the company says supports potential once- or twice-yearly dosing.
Looking ahead, Wave intends to start the Phase 2a portion of the INLIGHT program in the second quarter of 2026. That stage will recruit people with higher BMI in the 35-50 kg/m2 range and with comorbidities. The company expects the Phase 2a study to yield larger improvements in body composition and weight loss, results that will help guide development of WVE-007 across indications that may include obesity, MASH, type 2 diabetes, and cardiovascular disease.
The current obesity drug market is noted by the company to be dominated by major players Novo Nordisk and Eli Lilly.
Key points
- Interim Phase 1 results: single 240 mg dose produced a placebo-adjusted 14% reduction in visceral fat at six months in a 32-person cohort with average BMI of 32 kg/m2.
- Body-composition gains included a 16.5% improvement in visceral fat-to-muscle ratio and increases in lean mass; modest reductions in waist circumference (3.3%) and body weight (0.9%) were also reported.
- WVE-007 was generally well tolerated up to 600 mg; Serum Activin E reductions persisted through at least seven months with mean maximum reductions up to 88%, supporting infrequent dosing potential.
Risks and uncertainties
- Small cohort size and lower baseline BMI - the 240 mg cohort enrolled 32 participants with average BMI of 32 kg/m2, which is substantially lower than the ~37 kg/m2 typically seen in Phase 2 and 3 obesity studies; this may limit direct comparability of outcomes.
- Future study outcomes - Wave plans a Phase 2a that will enroll higher-BMI participants with comorbidities in Q2 2026; the company expects larger effects but those results remain to be seen.
- Competitive market dynamics - the obesity drug market is currently dominated by established players, which could affect future commercial prospects.
These results provide early clinical signals on body composition and a tolerability profile for WVE-007, while the company prepares to test the therapy in a population with higher BMI and additional health conditions. Investors and industry observers will watch the Phase 2a readout and subsequent data to assess whether the compound’s effects expand in the intended target populations.